Introduction
With an incidence of between two and six per 1000 live full-term births, perinatal hypoxic-ischemic (H-I) injury is one of the most prevalent causes of neonatal brain injury, leading to death or lifelong disability [1, 2] . Although the utility of hypothermia in the reduction of death and disability is now well established in newborns with hypoxic-ischemic encephalopathy (HIE) [3] [4] [5] [6] [7] , as many as 40-50% of children with this condition still die or suffer long-term neurological damage [6, 8] . To minimize the neurological consequences of HIE, new and more-effective neuroprotective strategies are urgently required. The complex pathophysiology enables multiple targets at different time points of the disease process. For instance, in the early phase therapies are mainly concentrated on reduction of excitotoxic, oxidative and apoptotic mediators of injury (Figs. 1 and 2 and Table 1 ), whereas in the later stages reduction of inflammatory cytokines and stimulation of neurotrophic properties in the neonatal brain can be targeted to promote neuronal and oligodendrocyte regeneration (Fig. 2) .
Early phase
In this phase the basic cascade of H-I brain injury includes hypoxia, ischemia and energy depletion, which results in glutamate excitotoxicity. This in turn causes calcium influx, which triggers a cascade leading to apoptotic cell death via N-methyl-Daspartate (NMDA) and a-amino-3-hydroxyl-5-methyl-4-isoxazolepropionate (AMPA) glutamate receptors. With the influx of calcium and other ions, free radicals including superoxide anion (O 2 À ), hydroxyl radical (OH), singlet oxygen (O 2 ) and hydrogen peroxide (H 2 O 2 ) are produced; and lipases, proteases and endonucleases are also activated, triggering a series of cascade reactions resulting in cell death [9] . In addition, the inflammatory process can occur within 3-12 h after the reperfusion and reoxygenation response and is characterized by production of pro-and antiinflammatory cytokines [10] . Apoptotic cell death is also involved in newborn H-I brain injury, and it has been suggested that, in newborns, apoptosis might be more important in causing cell death after injury than necrosis [7, 11] . There is growing evidence that apoptosis is important in the early phase of H-I brain injury and can last for days and even weeks [12] . Mitochondrial impairment, especially damage to mitochondrial membrane integrity, is one of the key processes implicated in apoptotic cell death via the activation of a final executioner of cell death such as caspase 3 [13] . In this phase of neonatal H-I brain injury, the agents described below are applied to combat the pathologic changes and hold great promise for translation to clinical use.
Xenon
Xenon, a noble gas used as an anesthetic agent, has been shown to be neuroprotective in in vitro and in vivo experimental studies of H-I brain injury. It inhibits the NMDA receptor [14] and upregulates the pro-survival proteins Bcl-2 and brain-derived neurotrophic factor (BDNF) to ameliorate injury in asphyxiated rats [15] (Table 1) . When combined with hypothermia, xenon offers functional and histopathologic neuroprotection in asphyxiated newborn pigs [16] (Table 1) . Observed mechanisms of neuroprotection include preservation of cerebrovascular pressure reactivity, mean arterial blood pressure and cerebral perfusion pressureindependent of the insult severity and seizures [17] .
Xenon activates hypoxia-inducible factor 1a (HIF-1a) and its downstream effectors erythropoietin (EPO) and vascular endothelial growth factor (VEGF) to provide renal protection in an adult mouse model of ischemia-reperfusion injury [18] . It increases the efficiency of HIF-1a translation via modulation of the mammalian target of rapamycin (mTOR) pathway [18] . Breathing 50% xenon for up to 18 h with 72 h of cooling is feasible, with no adverse effects seen with 18 months follow-up in a Phase I study in newborns with HIE [19] (Table 2) . However, the high cost of xenon and its complicated administration as an inhaled gas requiring intubation and ventilation of the patient are major barriers to its clinical use.
Melatonin
Melatonin has multiple functions in treating H-I brain injury, including antiapoptotic, antioxidative and anti-inflammatory properties. Our studies in in vitro models of brain injury including primary cortical neurons, primary hippocampal neurons and/or primary striatal neurons have shown that melatonin inhibits mitochondrial cell death pathways, including caspase-dependent (cytochrome c/Smac release, caspase 1 and caspase 3 activation) and caspase-independent apoptosis-inducing factor (AIF) cell death pathways [20] [21] [22] [23] . Its other protective mechanism is activation of survival signal pathways [18, 19] . Melatonin has been shown to be neuroprotective in animal models of perinatal H-I brain injury [24] [25] [26] , with long-term effects lasting until adulthood [25] (Table 1) . Low-dose melatonin (0.1 mg/kg/day) administered to the mother over 7 days at the end of pregnancy protects against the effects of birth asphyxia in an animal model [27] (Table  1) . Melatonin is a potent free radical scavenger as well as an indirect antioxidant. The levels of free iron, F(2)-isoprostanes and F(4)-neuroprostanes have been shown to be significantly lower in H-I melatonin-treated rats compared with untreated H-I animals [28] . At the same time, melatonin stimulates gene expression as well as activates superoxide dismutase (SOD), catalase, G6PD and glutathione reductase in the brain tissue of hypoxic neonatal rats [29] (Table 1) . Melatonin in combination with topiramate (TPM; an AMPA/kainate receptor antagonist) significantly reduces brain infarct volume and number of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL)-positive cells in a rat model of H-I brain injury [30] . When combined with hypothermia, melatonin enhances neuroprotection by reduction of the H-I-induced increase in clinically relevant biomarkers in the deep grey matter of newborn piglets [31] . In a study limited by small sample size, there were significant reductions in malondialdehyde and nitrite/nitrate levels in asphyxiated human newborns given melatonin [32] . In recent years, the use of melatonin in human newborns for conditions of oxidative stress such as asphyxia, sepsis and respiratory distress syndrome has 
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FIGURE 1
The classification of present neuroprotective agents for early treatment of neonatal hypoxic-ischemic brain injury. demonstrated a good safety profile with no significant complications [33] (Table 2) . A randomized control pilot study showed that the combination of melatonin and hypothermia administered to infants with moderate-to-severe H-I brain injury was efficacious in reducing oxidative stress and improving survival with favorable neurodevelopmental outcomes at 6 months of age [34] (Table 2) . However, concern has been raised with higher doses of melatonin of 10 mg/kg/h resulting in hypotension in newborn piglets [31] . Also, because there is no licensed intravenous formulation of melatonin available, a study of formulated melatonin cautioned against extrapolation of dosage from adult studies because of differing pharmacokinetic profiles in preterm infants [35] . 
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FIGURE 2
Molecular mechanisms involved in neonatal hypoxic-ischemic (H-I) brain injuries and molecular targets for present drug developments. Pathogenesis is chronologically divided into three stages: early phase, reperfusion and later phase. In the early phase, energy deprivation caused by hypoxia-ischemia triggers a failure of ATP-dependent Na + -K + pump, leading to intracellular accumulation of Na + , Ca 2+ and water, which results in cytotoxic edema and acute necrosis. At same time, hypoxia-ischemia induces the transcription of inflammation factors and neurotrophic factors for later-phase repair by the hypoxia-inducible factor (HIF)-1a pathway. The accumulation of glutamate caused by impaired reuptake from presynapsis leads to depolarization of cell membrane, increasing the influx of Ca 2+ from the intracellular endoplasmic reticulum (ER) and mitochondrion, which in turn activates the intrinsic caspase-dependent apoptosis pathway. Excessive cytoplasmic Ca 2+ also activates the expression of proinflammatory genes, such as interleukins (ILs) and tumor necrosis factor (TNF)-a, by the nuclear factor (NF)-kB pathway. Reoxygenation during reperfusion produces substantial radical oxygen species (ROS), radical nitrogen species (RNS) and peroxynitrite (ONOO À ), which exacerbates the damage to the cell membrane and DNA and induces cell apoptosis. In the later phase the proinflammatory factors expressed in the early phase activate an extrinsic caspase-independent apoptosis pathway and attenuate neuronal injury. The neurotrophic factors activate a protective pro-survival pathway by AKT/protein kinase B (PKB). The molecular targets of the agents described in this paper are framed in orange. Abbreviations: APAF1, apoptosis protease activating factor-1; BAK, Bcl-2 agonist killer 1; BAX, Bcl-2-associated X protein; BID, BH3 interacting domain death; Cyto.C, cytochrome C; IKK, inhibitor of nuclear factor kappa-B kinase; CaM, calmodulin; FADD, FAS-associated death domain; cFLIP, cellular Fas-associated death domain-like interleukin-1b-converting enzyme (FLICE)-like inhibitory protein; IkBa, inhibitory subunit of nuclear factor kappa B alpha; pJNK1, c-Jun amnion terminal kinase 1; PKC, protein kinase C; SMAC/ DIABLO, second-mitochondrial-derived activator of caspases; TRAF2, TNF-receptor-associated factor-2; PHD2, prolyl hydroxylase domainprotein 2; VHL-E3, von Hippel-Lindau ligase; EPO, erythropoietin; VEGF, vascular endothelial growth factor; AIF, apoptosis-inducing factor. www.drugdiscoverytoday.com 1375
Reviews POST SCREEN EPO exerts a neuroprotective effect by increasing glutathione peroxidase enzyme activity and decreasing lipid peroxidation levels in H-I brain injury in neonatal rats [41] (Table 1) . The safety and pharmacokinetics of EPO given in conjunction with hypothermia for newborns with HIE has been established in Phase I trials [42, 43] (Table 2) . Repeated low-dose rEPO reduced the risk of disability for infants with moderate HIE, without apparent sideeffects [44] (Table 2) . However, a number of studies also report that EPO administration could have detrimental effects on normal neuronal development. The proliferation of neuronal stem cells elicited by EPO could have a negative impact on multipotent progenitor cells [45] . Because the expression of EPO and EPOR is significant during brain development, it is conceivable that exogenous EPO administration could inhibit endogenous EPO expression [46] . In addition, EPO inhibits apoptosis, which could be a necessary physiological component for normal brain development [47] .
Allopurinol
Allopurinol, a xanthine oxidase inhibitor and free radical scavenger, reduces cerebral edema and perinatal H-I brain damage in P7 rat pups [48] (Table 1) . It provides neuroprotection to hypoxic piglets by increasing brain tissue levels of adenosine and inosine [49] (Table 1) . However, a meta-analysis of three clinical trials including 114 infants has failed to show clinically important benefits for newborn infants with HIE [50] (Table 2 ). The lack of benefit noted in one trial could be the result of selection of severely affected babies and therapy started too late to reduce the early reperfusion-induced free-radical surge [51] . However, even earlier administration of allopurinol by maternal treatment during labor with fetal hypoxia does not significantly lower neuronal damage markers in cord blood, although there might be a beneficial treatment effect specific to girls [52] (Table 2 ).
NMDA and AMPA receptor antagonists
Despite concerns that blockage of developmental processes like glutamatergic signaling can harm the developing brain, some NMDA and AMPA receptor antagonists like magnesium sulphate, TPM and memantine have been shown to be neuroprotective in animal models of newborn H-I brain injury.
Magnesium sulfate
Magnesium is a naturally occurring NMDA receptor antagonist. It also decreases levels of inflammatory cytokines and platelet aggregation and is essential for glutathione synthesis. In a newborn rat model of H-I brain injury, magnesium inhibits apoptotic neuronal death by reduction of caspase 3 or TUNEL-positive cells [53] (Table  1) , prevents H-I-induced sensorimotor deficits [54] (Table 1) and significantly reduces the percentage of infarcted brain volume and TUNEL positivity, alone or in combination with melatonin [55] .
A systematic review of preclinical studies has shown that magnesium is not consistently neuroprotective in perinatal hypoxiaischemia [56] . A meta-analysis of five clinical randomized control trials (RCTs) where magnesium was given within the first 24 h after birth in HIE babies as a neuroprotective agent showed improvement in short-term outcomes without significant increase in adverse effects [57] (Table 2 ). This supports the need for further adequately powered trials to determine if there are long-term benefits of magnesium and to confirm its safety. (Table 1) . In a newborn piglet model of H-I brain injury, there was a significant reduction of neuronal cell loss in animals treated with TPM, although an increase in apoptosis in the frontal white matter of the drug-treated group was of concern [60] (Table 1) . A pilot study to assess the safety and efficacy of TPM in neonates with HIE treated with hypothermia is currently ongoing [61] (Table 2) .
Memantine
The clinically available NMDA receptor antagonist memantine attenuates NMDA-evoked currents in developing white-matter oligodendrocytes in a rat model of H-I brain injury, reduces the acute loss of developing and mature oligodendrocytes as well as reduces cerebral mantle thickness seen at postnatal day 21 [62] ( Table 1) . At neuroprotective doses memantine is relatively safe, because it does not increase neuronal apoptosis and has no longterm alterations in the expression of markers of synaptogenesis [63] .
NF-kB inhibitors
Tat-NEMO-binding domain peptide
Nuclear factor (NF)-kB is a ubiquitously expressed transcription factor that regulates apoptotic genes and expression of inflammatory mediators. Several reports suggest that the NF-kB signaling pathway could be an important therapeutic target in infectionsensitized neonatal H-I brain injury [64] . However, systemic application of Tat-NEMO-binding domain (TAT-NBD) peptidespotent NF-kB inhibitors -has yielded mixed results in pure models of H-I injury that are not sensitized by infection [65, 66] . TAT-NBD treatment markedly reduces brain injury by preventing mitochondrial accumulation of p53, cytochrome c release and activation of caspase 3 in H-I rats [67] ( Table 1) . Early NF-kB activation contributes to neonatal H-I brain damage, whereas late NF-kB activation Drug Discovery Today Volume 20, Number 11 November 2015 REVIEWS Collection, preparation and infusion of fresh autologous cord blood is feasible with no significant clinical problems attributable to cells [99] www.drugdiscoverytoday.com 1377
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provides endogenous neuroprotection by upregulation of antiapoptotic molecules like Bcl-2 and Bcl-xL. Therefore, inhibition of early NF-kB activity is neuroprotective only when late NF-kB activity is maintained [68] (Table 1) .
PDTC and IDR-1018
Ammonium pyrrolidinedithiocarbamate (PDTC) is neuroprotective in a rat model of H-I brain injury by inducing the dephosphorylation of Akt and glycogen synthase kinase-3b and the inhibition of activation and nuclear translocation of NF-kB and downstream matrix metalloproteinase (MMP)-9 activity [69] ( Table 1 ). In a clinically relevant mouse model, IDR-1018 reduces LPSinduced H-I perinatal brain injury and regulates molecules of inflammatory pathways [70] (Table 1) .
Nitric oxide synthase inhibitors
Owing to the toxic effects of excessive formation of nitric oxide (NO) free radicals in the early reperfusion/reoxygenation phase, inhibition of nitric oxide synthase (NOS) production by selective and non-selective NOS inhibitors could ameliorate perinatal brain damage after H-I brain injury. In this section we summarize the therapeutic effects of important NOS inhibitors.
2-Iminobiotin
2-Iminobiotin (2-IB), known for its antioxidative effect, is a selective inhibitor of neuronal NOS (nNOS) and inducible NOS (iNOS).
Significant neuroprotection is elicited by reduction of heat shock protein (HSP)70 expression, a marker of brain injury, using 2-IB in 12-day-old rats (P12) following H-I brain injury [71] (Table 1 ). In addition, the neuroprotective effect of 2-IB is gender-dependent, because it prevents the increase of cytochrome c levels and caspase 3 only in females [72] (Table 1) . 2-IB causes reduction in nitrotyrosine, an early marker of cellular injury in perinatal hypoxiaischemia, via inhibition of nNOS and iNOS. [73] . However, impairment of cognitive functions by 2-IB through nNOS inhibition in adult rats is of concern [74] .
Aminoguanidine and indomethacin
Neuroprotection by selective inhibition of iNOS with the iNOS inhibitor aminoguanidine has been reported in several studies in neonatal animals. Aminoguanidine reduces NO production by suppressing the second peak of biphasic increase in NO metabolites, markedly reducing infarct size in a neonatal ischemic rat model [75] (Table 1) . Indomethacin, a nonselective cyclooxygenase inhibitor, reduces neonatal rat brain damage after perinatal H-I injury. Indomethacin administration before hypoxic ischemia and followed by aminoguanidine is effective in reducing infarct area in newborn rats without an effect on iNOS expression [76] (Table 1) . Indomethacin administration after H-I brain injury is neuroprotective by inhibition of caspase activity and restoration of glutathione levels, although aggravation of lipid peroxidation-induced ischemia is of concern [77] ( Table 1) .
7-Nitroindazole and JI-8
Selective inhibition of nNOS with the commonly used nNOS inhibitor 7-nitroindazole and novel nNOS inhibitor JI-8 has been studied in the newborn H-I brain injury model. JI-8 treatment significantly decreases NOS activity (39%) in fetal rabbit brain homogenates acutely after H-I injury; JI-8 was superior to 7-nitroindazole and a saline vehicle in terms of protective effect on neurobehavior [78] ( Table 1) .
Nonselective NOS inhibitors such as nitro-L-arginine administered during the early post-H-I period have been reported to reduce free-radical-mediated reperfusion injury in the neonatal brain [79] . In P12 rat pups the combined inhibition by nNOS and iNOS reduces H-I-induced brain injury and improves long-term outcome [80] . An increasing number of studies show that nonselective NOS inhibitors, especially those with prominent inhibitory effects on eNOS, prevent adequate post-H-I brain perfusion, eventually leading to increased production of free radicals and aggravation of brain damage [81] .
Later phase
In the later phase of H-I brain injury in newborns, the intrinsic ability of the immature brain to ameliorate damage induced by hypoxia-ischemia is dependent on the activation of inflammatory cytokines, production of trophic factors and endogenous regenerative activity. Cytokines include tumor necrosis factor (TNF)-a, IL-1, IL-6, IL-8 and IL-10; and transcription factors such as NF-kB and c-Jun N-terminal kinase (JNK) have a central role in this phase [10] . BDNF, epidermal growth factor (EGF), insulin-like growth factor (IGF)-1, VEGF, nerve growth factor (NGF), granulocyte-colonystimulating factor and other factors such as EPO also have crucial roles. These factors have been reported to exert neuroprotective, antioxidative and antiapoptotic effects and to inhibit the cytotoxicity of excitatory amino acids, stabilize intracellular calcium concentration and suppress calcium overload [82] . Supplementation of deficient growth factors could therefore reduce or prevent delayed H-I-induced brain damage. In addition, promoting neuronal regeneration with endogenous stem cells or stem cell transplantation is also a possible intervention in neonatal H-I brain damage.
Growth factors
BDNF
Pretreatment with BDNF protects against brain injury and spatial memory impairment in H-I neonatal rats [83] (Table 1) . BDNF protects neural cells from apoptosis by blocking caspase 3 activation and activating neuronal ERK in the neonatal brain. BDNF also supports the survival of existing neurons and encourages the growth and differentiation of new neurons and synapses in newborns with H-I brain injury [84] . In addition, because BDNF is a neurotrophin that binds to the TrkB and p75NTR receptors, the TrkB-specific agonist antibody significantly inhibits caspase 3 activation and increases neuronal survival following H-I brain injury [85] (Table 1) .
IGF-1
IGF-1, an anabolic pleiotrophic factor, is produced by astrocytes. The neuroprotection effect of IGF-1 is associated with its antiapoptotic and mitogenic effects [86] (Table 1) . Delayed administration of IGF-1 rescues oligodendrocyte progenitors in the immature white matter and promotes myelination following H-I injury [87] ( Table 1) . Subcutaneous administration of IGF-1 at 24 and 48 h of recovery significantly reduces H-I injury to immature rat brains and improves long-term memory and cognitive behavior [88] . Further studies infer that the therapeutic effects of IGF-1 probably involve its ability to prevent delayed apoptosis of primary cortical neurons, which means that IGF-1 could be useful not only in the later phases but also in the early phases of H-I brain injury [88] .
Basic fibroblast growth factor
Basic fibroblast growth factor (bFGF), a polypeptide growth factor, is neuroprotective in H-I neonatal rats by preventing NMDAinduced neurotoxicity [89] (Table 1) and upregulating nestin and GAP-43 expression [90, 91] (Table 1 ). In addition, protecting neural cells from apoptosis by upregulating bone morphogenetic protein (BMP)4 was assumed to be another element of the protective effect of bFGF [92] . EGF can stimulate neurogenesis by activation of the endogenous NSCs residing in the subventricular zones and subgranular zone of the dentate gyrus, as shown in rodent pup models [93] .
Stem cell therapy
Stem cell therapy is effective in promoting functional recovery in animal models of neonatal H-I brain injury [94] . Stem cell types used for treating long-term brain damage after neonatal H-I brain injury include neuronal stem cells (NSCs), mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), cord blood stem cells and amniotic fluid stem cells.
Stimulating endogenous NSCs to differentiate into neurons or transplantation of exogenous NSCs are two potentially important therapies to reduce long-term brain damage after perinatal H-I injury. We and other researchers have also reported that the transplantation of umbilical cord blood mononuclear cells regulates the differentiation of endogenous NSCs in H-I neonatal rats via the Hedgehog signaling pathway [95, 96] . MSCs are capable of differentiation into a variety of tissue-specific cells. Treatment of ischemic brain injury by transplantation of MSCs in neonatal animal models is effective in reducing lesion volume and improving functional outcome by secretion of several growth factors that are known to contribute to neuroprotection, including colonystimulating factor-1, stem cell factor, VEGF, bFGF, NGF and BDNF, cytokines and other bioactive molecules to regulate damage and repair processes [97] (Table 1) . Intracranial administration of MSCs as late as 3-10 days after H-I insult reduces histological damage and improves sensorimotor outcome in neonatal mouse and rat models of H-I brain injury [98] .
The pluripotent capacity of stem cells from human umbilical cord blood allows simultaneous targeting of multiple neuropathologic events initiated by H-I insult in animals. Clinical trials of autologous cord blood cells for the treatment of neonatal HIE has established its feasibility and safety [99] (Table 2) . Although there are strong preclinical data available that show some types of stem cells are effective neurotherapies, there are still many variables to explore to ensure clinicians can identify the right cells for the right patients at the right time to achieve the overarching goal of improving outcomes for neonates suffering brain injury.
Erythropoietin
The rather strong neurotrophic capability of EPO is thought to be caused by induction of neural progenitor cell proliferation and prevention of neuronal cell death. EPO induces significant elongation of neurite outgrowth by upregulation of BDNF and the expression of other neurotropic factors [100] (Table 1) . It promotes neurogenesis and oligodendrogliosis at early and late time points of neonatal stroke [101] . In addition, the multifaceted action of EPO also includes increasing axonal sprouting, revascularization, reducing white matter injury and inducing recovery of structural and functional connectivity of white matter as well as somatosensory cortical function, which are essential for plasticity and remodeling of the injured brain in the late phase of perinatal H-I brain injury [100, 102] (Table 1) .
Concluding remarks and future challenges
It is disappointing that, despite the numerous drugs that have proven to be beneficial in animal models, hypothermia is the only intervention against H-I brain injury that has translated to clinical use in humans. This gap could be partly due to limitations of preclinical studies in terms of methodological concerns, investigator bias, poor appreciation of drug pharmacokinetics and pharmacodynamics and the possible use of clinically irrelevant models and endpoints. In addition, the choice of species and strains of animals that closely resemble the newborn human brain and its response to injury is lacking. Moreover, the pattern of injury in rodents with relatively small lissencephalic brains with less white matter is different from that of humans. Gender is also a factor, because females appear to benefit more from neuroprotective interventions after H-I brain injury, such as hypothermia, EPO and 2-IB [72, 103] , although some studies showed treatment benefit of EPO in males more than females [104] . It is increasingly clear that exploiting a single pathophysiological pathway might not be sufficient to combat neonatal H-I brain injury. Further studies should be directed toward use of synergistic agents that act on multiple processes that characterize the disease. Promising neuroprotective drugs should be studied in combination with hypothermia, because temperature change can greatly alter the pharmacokinetics and pharmacodynamics of various drugs. Adequate study of the doseresponse curve for drugs, evaluating potential therapies in multiple models and with higher species, attention to randomization and blinding of investigators to outcome measures, and more statistical rigor, are some of the measures needed to make preclinical studies more robust to guide clinical trials appropriately. An international panel of experts tasked with deciding which neuroprotective agents are ready for bench-to-bedside translation assigned the highest score to melatonin, followed by EPO, N-acetylcysteine, EPOmimetics, allopurinol, xenon, resveratrol, vitamin C/E, memantine and TPM [105] for postnatal neuroprotection in newborn HIE. We hope that one or more of these promising drugs currently in the initial phases of clinical trials will successfully translate to clinical use in the near future and offer hope to millions of babies with this devastating condition.
Conflicts of interest
The authors declare that this work contains no potential conflicts in terms of commercial interests.
